- Home
- EFOR vs VOR Comparison
EFOR vs VOR Comparison
Compare EFOR & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EFOR | VOR |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EFOR | VOR |
|---|---|---|
| Price | $33.68 | $22.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 537.3K | ★ 690.7K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $3,980,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.90 | $6.50 |
| 52 Week High | $33.78 | $49.95 |
Technical Indicators
Market Signals| Indicator | EFOR | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 51.39 |
| Support Level | $30.27 | $21.90 |
| Resistance Level | N/A | $24.44 |
| Average True Range (ATR) | 1.63 | 1.18 |
| MACD | -0.27 | -0.26 |
| Stochastic Oscillator | 93.13 | 26.06 |
Price Performance
Historical ComparisonAbout EFOR Everforth Inc. Common Stock
Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.